Atria Investments Inc Has $883,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atria Investments Inc boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 54.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,358 shares of the medical equipment provider's stock after purchasing an additional 2,929 shares during the period. Atria Investments Inc's holdings in Zimmer Biomet were worth $883,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Roman Butler Fullerton & Co. purchased a new position in shares of Zimmer Biomet during the 4th quarter worth $473,000. Geode Capital Management LLC boosted its stake in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after acquiring an additional 125,852 shares during the last quarter. M&T Bank Corp boosted its stake in shares of Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock worth $2,884,000 after acquiring an additional 8,709 shares during the last quarter. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet during the 4th quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC purchased a new position in shares of Zimmer Biomet during the 4th quarter worth $654,000. Institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. JMP Securities restated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial restated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $124.15.

Remove Ads

Zimmer Biomet Stock Up 2.4 %

ZBH stock traded up $2.53 during midday trading on Friday, reaching $110.10. 2,301,092 shares of the company were exchanged, compared to its average volume of 1,929,614. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The stock's 50-day simple moving average is $105.72 and its 200 day simple moving average is $107.06. The company has a market cap of $21.92 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business posted $2.20 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet's payout ratio is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.